 |
|
Colon and Rectal Cancer Trial Results
16. Capecitabine (Xeloda ®) an Alternative in Post-Surgery Treatment of Stage III Colon Cancer
(Posted: 07/27/2005) - After surgery to remove their tumors, patients with stage III colon cancer who took pills containing the drug capecitabine (Xeloda®) survived about as long without relapse, and with more tolerable side effects, as those treated with a fluorouracil (5-FU) plus leucovorin regimen, according to the June 30, 2005, issue of the New England Journal of Medicine.
17. Vitamin E Does Not Protect Women Against Cancer
(Posted: 07/27/2005) - Vitamin E supplements do not protect healthy women age 45 or older against cancer, according to the 10-year, randomized Women's Health Study. However, it remains unclear whether vitamin E might yet prove protective in other groups of people.
18. Low-Dose Aspirin Fails to Protect Women Against Cancer
(Posted: 07/27/2005) - Low-dose aspirin taken every other day failed to protect women from developing cancer, according to results from a 10-year, randomized trial called the Women's Health Study. However, researchers say that more studies are needed to determine whether moderate or high doses of aspirin may yet prove protective.
19. Sigmoidoscopy Screening Misses Cancer More Often in Women Than in Men
(Posted: 06/27/2005) - Researchers comparing two common methods of screening symptom-free patients for signs of possible colorectal cancer found that compared to colonoscopy, the less-invasive technique of flexible sigmoidoscopy missed two-thirds of tumors or potential tumors in women, twice as many as it missed in men.
20. Adding Bevacizumab (Avastin®) Improves Outcomes in Advanced Colorectal Cancer
(Posted: 05/14/2005, Reviewed: 05/01/2007) - Patients with advanced colorectal cancer lived longer and went longer without disease progression when their FOLFOX chemotherapy regimen was supplemented with bevacizumab (Avastin®), according to findings presented at the American Society of Clinical Oncology.
< Previous 1 2 3 4 5 6 7 Next >
|
|
|
